Lavipharm S.A. (BXA0) Stock Statistics & Valuation Metrics
Total Valuation
Lavipharm S.A. has a market cap or net worth of EUR 262.32M. The enterprise value is EUR 157.29M.
- Market Cap
- EUR 262.32M
- Enterprise Value
- EUR 157.29M
Share Statistics
Lavipharm S.A. has 170,778,490 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 170,778,490
- Owned by Insiders
- ―
- Owned by Institutions
- 0.24%
Financial Efficiency
Lavipharm S.A.’s return on equity (ROE) is 0.17 and return on invested capital (ROIC) is 11.08%.
- Return on Equity (ROE)
- 0.17
- Return on Assets (ROA)
- 0.07
- Return on Invested Capital (ROIC)
- 11.08%
- Return on Capital Employed (ROCE)
- 0.05
- Revenue Per Employee
- 173.03K
- Profits Per Employee
- 29.35K
- Employee Count
- 306
- Asset Turnover
- 0.42
- Inventory Turnover
- 1.41
Valuation Ratios
The current PE Ratio of Lavipharm S.A. is 9.91. Lavipharm S.A.’s PEG ratio is -0.17.
- PE Ratio
- 9.91
- PS Ratio
- 0.21
- PB Ratio
- 0.21
- Price to FCF
- -0.26
- Price to Operating Cash Flow
- 2.45
- PEG Ratio
- -0.17
Income Statement
In the last 12 months, Lavipharm S.A. had revenue of 52.95M and earned 8.98M in profits. Earnings per share was 0.05.
- Revenue
- 52.95M
- Gross Profit
- 23.73M
- Operating Income
- 4.26M
- Pretax Income
- 3.60M
- Net Income
- 8.98M
- EBITDA
- 10.27M
- Earnings Per Share (EPS)
- 0.05
Cash Flow
In the last 12 months, operating cash flow was 4.80M and capital expenditures -9.64M, giving a free cash flow of -4.85M billion.
- Operating Cash Flow
- 4.80M
- Free Cash Flow
- -4.85M
- Free Cash Flow per Share
- -1.50
Dividends & Yields
Lavipharm S.A. pays an annual dividend of EUR 0.02, resulting in a dividend yield of 1.34%
- Dividend Per Share
- EUR 0.02
- Dividend Yield
- 1.34%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -390.14%
- Earnings Yield
- 10.09%
Stock Price Statistics
- Beta
- 0.64
- 52-Week Price Change
- 98.08%
- 50-Day Moving Average
- 1.47
- 200-Day Moving Average
- 1.36
- Relative Strength Index (RSI)
- 52.41
- Average Volume (3m)
- 2,876
Important Dates
Lavipharm S.A. upcoming earnings date is ―, TBA (Not Confirmed).
- Last Earnings Date
- Nov 17, 2025
- Next Earnings Date
- ―
- Ex-Dividend Date
- Jul 17, 2025
Financial Position
Lavipharm S.A. as a current ratio of 1.15, with Debt / Equity ratio of 53.11%
- Current Ratio
- 1.15
- Quick Ratio
- 0.62
- Debt to Market Cap
- 0.13
- Net Debt to EBITDA
- 2.19
- Interest Coverage Ratio
- 2.04
Taxes
In the past 12 months, Lavipharm S.A. has paid -5.06M in taxes.
- Income Tax
- -5.06M
- Effective Tax Rate
- -1.40
Enterprise Valuation
Lavipharm S.A. EV to EBITDA ratio is 4.35, with an EV/FCF ratio of -0.76.
- EV to Sales
- 0.62
- EV to EBITDA
- 4.35
- EV to Free Cash Flow
- -0.76
- EV to Operating Cash Flow
- 7.24
Balance Sheet
Lavipharm S.A. has EUR 5.59M in cash and marketable securities with EUR 28.14M in debt, giving a net cash position of -EUR 22.55M billion.
- Cash & Marketable Securities
- EUR 5.59M
- Total Debt
- EUR 28.14M
- Net Cash
- -EUR 22.55M
- Net Cash Per Share
- -EUR 0.13
- Tangible Book Value Per Share
- EUR 0.02
Margins
Gross margin is 41.93%, with operating margin of 6.89%, and net profit margin of 2.14%.
- Gross Margin
- 41.93%
- Operating Margin
- 6.89%
- Pretax Margin
- 5.78%
- Net Profit Margin
- 2.14%
- EBITDA Margin
- 14.35%
- EBIT Margin
- 9.98%
Analyst Forecast
The average price target for Lavipharm S.A. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- 31.81%
- EPS Growth Forecast
- 48.03%
